TetraLogic drops proposed price for IPO

Cancer company TetraLogic Pharmaceuticals Corp. (Malvern, Pa.) amended its IPO and said it now plans to sell 6.5 million shares at $7. At the $7 price, the company would raise $45.5 million and be valued at $143.3 million. Late last month, TetraLogic was rumored to have postponed its IPO. Earlier in November, the company had amended its IPO and said it planned to sell 6.4 million shares at $13-$15. Oppenheimer; Guggenheim Securities; and Needham are underwriters. ...